Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6

1.

Phosphoproteomic screen identifies potential therapeutic targets in melanoma.

Tworkoski K, Singhal G, Szpakowski S, Zito CI, Bacchiocchi A, Muthusamy V, Bosenberg M, Krauthammer M, Halaban R, Stern DF.

Mol Cancer Res. 2011 Jun;9(6):801-12. doi: 10.1158/1541-7786.MCR-10-0512. Epub 2011 Apr 26.

2.

Direct resequencing of the complete ERBB2 coding sequence reveals an absence of activating mutations in ERBB2 amplified breast cancer.

Zito CI, Riches D, Kolmakova J, Simons J, Egholm M, Stern DF.

Genes Chromosomes Cancer. 2008 Jul;47(7):633-8. doi: 10.1002/gcc.20566.

3.

SHP-2 regulates cell growth by controlling the mTOR/S6 kinase 1 pathway.

Zito CI, Qin H, Blenis J, Bennett AM.

J Biol Chem. 2007 Mar 9;282(10):6946-53. Epub 2007 Jan 17.

4.

Gain-of-function/Noonan syndrome SHP-2/Ptpn11 mutants enhance calcium oscillations and impair NFAT signaling.

Uhlén P, Burch PM, Zito CI, Estrada M, Ehrlich BE, Bennett AM.

Proc Natl Acad Sci U S A. 2006 Feb 14;103(7):2160-5. Epub 2006 Feb 3.

5.

SHP-2 positively regulates myogenesis by coupling to the Rho GTPase signaling pathway.

Kontaridis MI, Eminaga S, Fornaro M, Zito CI, Sordella R, Settleman J, Bennett AM.

Mol Cell Biol. 2004 Jun;24(12):5340-52.

6.

The major vault protein is a novel substrate for the tyrosine phosphatase SHP-2 and scaffold protein in epidermal growth factor signaling.

Kolli S, Zito CI, Mossink MH, Wiemer EA, Bennett AM.

J Biol Chem. 2004 Jul 9;279(28):29374-85. Epub 2004 May 7.

Supplemental Content

Support Center